Comparative pathogenesis of Ebola virus and Reston virus infection in 1 humanized mice 2

Filoviruses of the genus Ebolavirus include five species with marked differences in their ability to cause disease in humans. From the highly virulent Ebola virus to the seemingly nonpathogenic Reston virus, case-fatality rates can range between 0-90%. In order to understand the molecular basis of these differences it is imperative to establish disease models that recapitulate human disease as faithfully as possible. Non-human primates are the gold-standard models for filovirus pathogenesis, but comparative studies are skewed by the fact that Reston virus infection can be lethal for NHP. Here we have used HLA-A2 transgenic, NOD-scid-interleukin 2g receptor knockout (NSG-A2) mice reconstituted with human hematopoiesis to compare Ebola virus and Reston virus pathogenesis in a humanlike environment. While significantly less pathogenic than Ebola virus, Reston virus killed 20% of infected mice, a finding that was linked to exacerbated inflammation and viral replication in the liver. In addition, ‘humanized’ mice recapitulated the case-fatality ratios of different Ebolavirus species in humans. Our findings point out at humanized mice as a putative model to test the pathogenicity of newly discovered filoviruses, and warrants further investigations on Reston virus pathogenesis in humans. Research Infectious disease Virology

[1]  J. Sidney,et al.  Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection , 2019, Cell.

[2]  E. Rubin,et al.  The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses , 2018, Nature Microbiology.

[3]  Robert J. Fischer,et al.  Outbreaks in a Rapidly Changing Central Africa - Lessons from Ebola. , 2018, The New England journal of medicine.

[4]  M. Shi,et al.  The evolutionary history of vertebrate RNA viruses , 2018, Nature.

[5]  H. Feldmann,et al.  Post-exposure treatments for Ebola and Marburg virus infections , 2018, Nature Reviews Drug Discovery.

[6]  C. Mire,et al.  Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus , 2016, The Journal of infectious diseases.

[7]  Timothy D. Flietstra,et al.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Lauren A. Cowley,et al.  Unique human immune signature of Ebola virus disease in Guinea , 2016, Nature.

[9]  K. Lokuge,et al.  Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. , 2015, Journal of Clinical Investigation.

[10]  G. Ippolito,et al.  Blood kinetics of Ebola virus in survivors and nonsurvivors. , 2015, The Journal of clinical investigation.

[11]  S. Günther,et al.  Delayed Disease Progression in Cynomolgus Macaques Infected with Ebola Virus Makona Strain , 2015, Emerging infectious diseases.

[12]  Rachel S. G. Sealfon,et al.  Clinical illness and outcomes in patients with Ebola in Sierra Leone. , 2014, The New England journal of medicine.

[13]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[14]  V. Borisevich,et al.  A Human Lung Xenograft Mouse Model of Nipah Virus Infection , 2014, PLoS pathogens.

[15]  X. Qiu,et al.  Ebola Virus Transmission in Guinea Pigs , 2014, Journal of Virology.

[16]  M. E. Miranda,et al.  Reston ebolavirus in humans and animals in the Philippines: a review. , 2011, The Journal of infectious diseases.

[17]  W. Ian Lipkin,et al.  Discovery of an Ebolavirus-Like Filovirus in Europe , 2011, PLoS pathogens.

[18]  H. Feldmann,et al.  Ebola haemorrhagic fever , 2011, The Lancet.

[19]  C. Basler,et al.  Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. , 2010, Journal of molecular biology.

[20]  A. Rothman,et al.  Dengue Virus Infection and Virus-Specific HLA-A2 Restricted Immune Responses in Humanized NOD-scid IL2rγnull Mice , 2009, PloS one.

[21]  B. Shacklett Can the New Humanized Mouse Model Give HIV Research a Boost? , 2008, PLoS medicine.

[22]  S. Dowell,et al.  Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. , 2007, The Journal of infectious diseases.

[23]  P. Jahrling,et al.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. , 2003, The American journal of pathology.

[24]  C. Boesch,et al.  Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d'Ivoire. , 1999, The Journal of infectious diseases.

[25]  P. Formenty,et al.  Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. , 1999, The Journal of infectious diseases.

[26]  C. Boesch,et al.  Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. , 1999, The Journal of infectious diseases.

[27]  H. Feldmann,et al.  Severity of Disease in Humanized Mice Infected With Ebola Virus or Reston Virus Is Associated With Magnitude of Early Viral Replication in Liver , 2017, The Journal of infectious diseases.

[28]  N. Tekin,et al.  Humanized Mice Reproduce Acute and Persistent Human Adenovirus Infection , 2017, The Journal of infectious diseases.

[29]  W. Ian Lipkin,et al.  Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda , 2008, PLoS pathogens.

[30]  P. Jahrling,et al.  Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. , 1996, Archives of virology. Supplementum.

[31]  Paul G. Thomas,et al.  Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination , 2022 .